Morbidity and Mortality Weekly Report (MMWR) Early Release Vol. 64 ; 1 May 2015
The Public Health Burden of Secondhand Exposure to Commercial Tobacco Smoke Secondhand smoke, the combination of smoke from burning commercial tobacco* products and the smoke breathed out by a perso...n who is smoking, is deadly.
more
Ce document d'orientation explique comment la distance physique (désignée dans les documents d'orientation précédents sous le nom de «distance sociale») peut aider à ralentir la transmission.
The objective of this document is to guide the preparation and implementation of national preparedness plans for the safety of substances ...ss="attribute-to-highlight medbox">of human origin during outbreaks of Zika virus infection, both in affected and non-affected areas.
more
This catalogue provides tools and information resources to support EU/EEA countries in addressing the challenging issue of vaccine hesitancy. The catalogue provides examples of practices that can se...rve as a resource for other countries. The project was developed in the context of ECDC’s support for EU/EEA Member States in prevention and control of vaccine-preventable diseases, including effective communication to promote immunisation.
more
Clinician Outreach and Communication Activity (COCA) Call
April 12, 2016
This document provides guidance on the application of non-pharmaceutical countermeasures to minimise the spread of the 2019 novel coronavirus (2019-nCoV) in the population. Some ...te-to-highlight medbox">of the measures proposed refer specifically to certain phases of the epidemic (containment or mitigation phases), and can be adapted depending on the assessed severity/impact of the infection. Other measures are valid for all phases of an epidemic.
The guidance is based on the current knowledge of the 2019-nCoV and evidence available on other viral respiratory pathogens, mainly the Severe Acute Respiratory Syndrome coronavirus (SARS-CoV), the Middle East Respiratory Syndrome-related coronavirus (MERS-CoV) and seasonal or pandemic influenza viruses.
more
Non-pharmaceutical interventions (NPI) are public health measures that aim to prevent and/or control SARS-CoV-2 transmission in the community. As long as there is no effective and safe vaccine to protect those at risk ...ight medbox">of severe COVID-19, NPI are the most effective public health interventions against COVID-19. These ECDC guidelines detail available options for NPI in various epidemiologic scenarios, assess the evidence for their effectiveness and address implementation issues, including potential barriers and facilitators.
more
A training tutorial for healthcare professionals
This ECDC tutorial presents the fundamental concepts of personal protective equipment (PPE) and barrier nursing to support preparedness in hospitals across Europe. It provides practical information o...n the proper use of PPE at the point of care, including technical requirements and procurement aspects
more
Scientific advice
Prevention and control of communicable diseases in prison settings.
Special Report
This report of the European Centre for Disease Prevention and Control (ECDC) w...as coordinated by Teymur Noori. Report review was provided by Andrew J. Amato-Gauci, Anastasia Pharris, Annabelle Gourlay, Amanda Mocroft, Jan C. Semenza, Denis Coulombier and Piotr Kramarz.
more
ECDC Technical Report
In line with ECDC’s recommendations provided in the ’Risk Assessment of HTLV-1/2 transmission by tissue/cell transplantation’ dated 14 March 2012, this Directive replaces the term ‘incidence’ with ‘prevalence... in the description of endemic areas of HTLV-1/2 infection. According to the new requirements ‘HTLV-1 antibody testing must be performed for donors living in, or originating from high-prevalence areas or with sexual partners originating from those areas or where the donor’s parents originate from those areas’ and this applies to both donors of non-reproductive tissues and cells and reproductive cells.
ECDC contracted experts from the Institut Pasteur in Paris to systematically review the published evidence on the distribution of HTLV-1 infection prevalence throughout the world and to identify high-prevalence countries and areas.
more
This technical guidance aims to provide guidelines to laboratories and relevant stakeholders in the European Union (EU), European Economic Area (EEA) and other countries in the WHO European region in making decisions on establishing sequencing capacities and capabilities, in making decisions on whic...h technologies to use and/or in deciding on the role of sequencing for SARS-CoV-2 diagnostics, research, outbreak investigations and surveillance. It addresses the most used sequencing technologies and their applications and proposes a central standardisation process to analyse and report the findings of SARS-CoV-2 genetic characterisations.
more